Quantitative MRI assessment of a novel direction modulated brachytherapy tandem applicator for cervical cancer at 1.5T.
CONCLUSIONS: This work demonstrated that the novel DMBT tandem applicator prototype has minimal artifact in T2-weighted images employed in clinical practice, suggesting the applicator might be a good candidate for MRI-guided adaptive brachytherapy. PMID: 27443448 [PubMed - as supplied by publisher]
Conclusions: In 3D brachytherapy of cervical cancer, GO and IPSA optimizations do not present a significant difference in target dose coverage; nevertheless, IPSA may reduce the maximum dose to normal tissue when compared with GO. PMID: 31523240 [PubMed]
Conclusions: When the facilities for MR-compatible applicators are not available, MR-based ISBT is feasible with PEEK catheters using available resources for advanced cervical cancer. Doses to HR-CTV and IR-CTV were achieved, restricting doses to OARs as per GEC-ESTRO guidelines. PMID: 31523230 [PubMed]
Authors: Mahantshetty U, Gudi S, Singh R, Sasidharan A, Sastri SC, Gurram L, Sharma D, Ganeshrajah S, Mg J, Badakh D, Basu A, James F, Swamidas JV, Kuppuswamy T, Bhalavat R Abstract Brachytherapy (BT) for locally advanced cervical cancer is vital for optimal outcomes. There is heterogeneity in brachytherapy treatment practice for cervical cancer across India. In an attempt to standardize various processes involved in cervical cancer brachytherapy, the expert members of the Indian Brachytherapy Society (IBS) developed a document related to radiation therapy treatment of cervical cancer with special emphasis on brach...
CHICAGO - Women in states where family planning clinics have closed received...Read more on AuntMinnie.comRelated Reading: ASTRO: Is hormone therapy after prostate surgery needed? 3D printing customizes brachytherapy for cervical cancer Contrast ultrasound identifies early cervical cancer FDG-PET/CT targets metastases in cervical, endometrial cancer Volumetric MR images boost cervical cancer treatment planning
This study assessed the efficacy of 3D-IGBT for elderly patients with cervical cancer.
CONCLUSIONS: IGABT using Vienna II applicator allows for appropriate target coverage in tumors extending into DP/LPW at the time of BT. Clinical use is feasible and results in good local control, DFS and OS with moderate rate of acute and late ≥G3 toxicity. PMID: 31495516 [PubMed - as supplied by publisher]
Correct tandem implantation for cervix cancer intracavitary brachytherapy may be challenging. We investigated whether suboptimal implantation can be related to patient and disease characteristics and may result in subsequent underutilization of brachytherapy in cervical cancer.
Brachytherapy (BT) is a mandatory part of curative treatment for locally advanced cervical cancer (LACC). In order to decide on optimum BT techniques, the tumor topography at BT may be classified into following categories: tumors limited to cervix at the time of BT with cconventional intracavitary BT techniques providing sufficient dose distribution (category 0); tumors with up to medial half parametrial infiltration (category I) may benefit from additional parallel interstitial needles [1,2]; tumors in the distal parametrium or beyond (category II) and tumors with significant (more than 2 –3 cm) vaginal infiltration (category III).
AbstractObjectiveDosimetric comparison of HIPO (hybrid inverse planning optimisation) and IPSA (inverse planning simulated annealing) inverse and forward optimisation (FO) methods in brachytherapy (BT) of breast, cervical and prostate cancer.MethodsAt our institute 38 breast, 47 cervical and 50 prostate cancer patients treated with image-guided interstitial high-dose-rate BT were selected. Treatment plans were created using HIPO and IPSA inverse optimisation methods as well as FO. The dose–volume parameters of different treatment plans were compared with Fr iedman ANOVA and the LSD post-hoc test.Resul...
Conclusion: Pelvic radiotherapy for GC increases the 5-year survival rate but with a negative impact on women's quality of life due to sexual dysfunction and radiation cystitis onset. With this study, CO2 laser therapy will be evaluated for the first time in GC survivors treated with radiotherapy. ClinicalTrials.gov registration number: NCT03714581. PMID: 31474161 [PubMed - as supplied by publisher]